Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Globally, an estimated 4,000 adolescent girls and young women become infected with HIV each week, with sub-Saharan Africa accounting for more than 60% of these new infections, according to the World ...

A new injectable drug known as lenacapavir could change how millions of people across the world and Africa in particular access HIV protective drugs, which historically have hard to come by.

WHO endorses biannual injectable Lenacapavir for HIV prevention. This long-acting PrEP offers hope for high-risk groups and ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

World Health Organization (WHO) recommends injectable lenacapavir for Human Immunodeficiency Virus (HIV) prevention ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Kenya has been selected as one of the 9 early adopter countries for the rollout of Lenacapavir (LEN), a long-acting ...

The World Health Organization (WHO) has issued new guidelines recommending the twice-yearly use of injectable lenacapavir ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...